Actively Recruiting

Age: 18Years +
All Genders
NCT06894576

Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis

Led by Ottawa Hospital Research Institute · Updated on 2025-03-25

1000

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

Sponsors

O

Ottawa Hospital Research Institute

Lead Sponsor

C

Canadian Institutes of Health Research (CIHR)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.

CONDITIONS

Official Title

Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Objectively documented distal and/or proximal deep vein thrombosis (DVT) of the limb (upper or lower extremity) and/or pulmonary embolism (PE), splanchnic vein thrombosis and/or cerebral sinus vein thrombosis with active cancer of any type
  • Planned anticoagulant treatment for cancer-associated thrombosis for at least 6 months at therapeutic dosing
  • Estimated life expectancy greater than 6 months
  • Willingness to provide informed consent
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Unusual site cancer-associated thrombosis such as gonadal vein thrombosis, ovarian vein thrombosis, or retinal vein thrombosis
  • Superficial vein thrombosis
  • Refusal to give informed consent more than 72 hours after starting anticoagulants
  • Age under 18 years old

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada, K1H8L6

Actively Recruiting

Loading map...

Research Team

K

Kristina Vrotniakaite-Bajerciene, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis | DecenTrialz